Regenerative Surgical Treatment of Peri-implant Defects

September 28, 2021 updated by: Juan Blanco Carrión, University of Santiago de Compostela

Regenerative Surgical Treatment of Peri-implant Defects. Submerged Versus Not Submerged

Does submerged healing of implants improve clinical and radiologic outcomes for the treatment of peri-implantitis? A number of recent systematic reviews have shown that the prevalence of periimplantitisin the population is high.

Nevertheless, there appears to be no consensus on treatment standards for the management of peri-implant diseases. Also, the significant variation in the empirical use of the available therapeutic modalities seems to result in moderately effective treatment outcomes. Animal and human case series-studies have shown improved outcomes when using a submerged healing approach. However, there seems to be no randomized controlled clinical studies comparing submerged/non-submerged healing efficacy for the treatment of peri-implantitis. Since current modalities for the treatment of peri-implantitis seem to result inmoderately effective outcomes, there is an urgency to investigate treatment strategies that will result in improved patient's benefits in terms of health.

Study Overview

Status

Recruiting

Detailed Description

The present study will be double-blinded randomized controlled clinical trial. Patients requiring surgical treatment of peri-implantitis after non-surgical therapy will beassigned to either:

Test group: submerged healing or Control group: non-submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.

The primary aim of this study is to evaluate whether submerged healing of implants willsignificantly improve the changes in marginal bone levels measured on X-rays 12months post-treatment compared to a non-submerged healing approach for the treatment of peri-implantitis.

Secondary aims include changes in clinical attachment levels, changes in probing pocket depth, recession, keratinized tissue, occurrence of bleeding on probing, suppuration on probing (PUS), marginal gingival recession (REC), full mouth plaque score (FMPS), full mouth bleeding score (FMBS), type of peri-implant bone defect, frequency and type of complications and implant loss.

Study Type

Interventional

Enrollment (Anticipated)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥18 years.
  • Systemically healthy patients.
  • Presence of at least 1 implant diagnosed with peri-implantitis (peri-implant probing pocket depth ≥6 mm in at least 1 aspect of the implant with bleeding and/or suppuration on probing and radiographically documented marginal bone loss ≥3mm) according to Renvert et al. (2018), after non-surgical therapy of periimplantitis, and a 4mm deep intrabony component.
  • Absence of mobility of the implants.
  • Individual implant-supported crown or partial fixed implant supported restoration (removable prosthesis will be excluded).
  • Patient's smoking ≤ 10 cigarettes/day.

Exclusion Criteria:

  • Non-removable prostheses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Test group
submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.

Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.

The surgeon will be blinded to the assignment of treatment until it is time to close the flaps.

EXPERIMENTAL: Control group
non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.

Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.

The surgeon will be blinded to the assignment of treatment until it is time to close the flaps.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes marginal bone level
Time Frame: baseline, 6 and 12 months
measured on periapical X-rays, from the shoulder of the implant to the bottom of the bone defect next to the implant at the mesial and distal surfaces. Mean marginal bone levels between mesial and distal measurements will be calculated.
baseline, 6 and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes Probing pocket depth
Time Frame: baseline, 6 and 12 months
distance from the margin gingival to the bottom of the peri-implant pouch. All clinical variables will be recorded with a Hu-friedy CP15 UNC millimeter probe in six points on each implant.
baseline, 6 and 12 months
Changes Clinical attachment level
Time Frame: baseline, 6 and 12 months
Distance from the implant shoulder or prosthetic abutment to the bottom of the peri-implant pocket.
baseline, 6 and 12 months
Change Reccesion
Time Frame: baseline, 6 and 12 months
distance from the margin of the peri-implant mucosa to the implant / abutment interface.
baseline, 6 and 12 months
Change Keratinized mucosa
Time Frame: baseline, 6 and 12 months
distance from the gingival margin up to the mucogingival line.
baseline, 6 and 12 months
Change blending on probing
Time Frame: baseline, 6 and 12 months
Registry of presence of bleeding by binary scale (1 bleed present / 0 bleed absent)
baseline, 6 and 12 months
Change supuration
Time Frame: baseline, 6 and 12 months
Pus presence register by scale binary (1 present / 0 absent)
baseline, 6 and 12 months
Change plaque score
Time Frame: baseline, 6 and 12 months
Registration of presence of plaque by binary scale on each surface (1 present / 0 absent), calculating the percentage of total surfaces in which plaque is detected by using a periodontal probe
baseline, 6 and 12 months
configuration of the bone defect
Time Frame: baseline
Based on the classification of Schwarz et al. (2007)
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Santiago Mareque, University of Santiago de Compostela

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2021

Primary Completion (ANTICIPATED)

December 1, 2021

Study Completion (ANTICIPATED)

December 1, 2022

Study Registration Dates

First Submitted

June 15, 2020

First Submitted That Met QC Criteria

June 18, 2020

First Posted (ACTUAL)

June 19, 2020

Study Record Updates

Last Update Posted (ACTUAL)

September 29, 2021

Last Update Submitted That Met QC Criteria

September 28, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • REGT_CT_19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Implant Site Pocket Infection

Clinical Trials on regenerative treatment periimplantitis

3
Subscribe